Immucell (ICCC) Consolidated Net Income (2010 - 2026)

Immucell (ICCC) has reported Consolidated Net Income for 17 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Consolidated Net Income rose 265.56% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at -$424808.0 (down 119.11% YoY), and the FY2025 full-year result was -$812481.0, up 52.09% from the prior year.
• Consolidated Net Income rose to $1.8 million in Q2 2026 per ICCC's latest filing, from -$2.6 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $1.8 million in Q2 2026 and bottomed at -$2.6 million in Q4 2025.
• Historically, Consolidated Net Income has averaged -$423290.6 across 5 years, with a median of -$655078.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Consolidated Net Income sank 1263.52% in 2022, then surged 1175.19% in 2024.
• Over 5 years, Consolidated Net Income stood at -$1.1 million in 2022, then soared by 106.72% to $76490.0 in 2023, then soared by 1175.19% to $975391.0 in 2024, then slumped by 368.77% to -$2.6 million in 2025, then surged by 169.98% to $1.8 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered $1.8 million, -$2.6 million, and -$139748.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.